vTv Therapeutics (VTVT) News Today $16.70 +0.65 (+4.05%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$16.40 -0.29 (-1.77%) As of 05/28/2025 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTVT Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period vTv Therapeutics (NASDAQ:VTVT) Stock Crosses Above Fifty Day Moving Average - Here's WhyvTv Therapeutics (NASDAQ:VTVT) Stock Price Passes Above 50-Day Moving Average - Time to Sell?May 26 at 5:14 AM | marketbeat.comvTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to InsulinMay 19, 2025 | globenewswire.comvTv Therapeutics (NASDAQ:VTVT) Stock Passes Above 50-Day Moving Average - Here's WhyvTv Therapeutics (NASDAQ:VTVT) Stock Passes Above 50-Day Moving Average - Should You Sell?May 18, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: vTv Therapeutics (VTVT) and Precision BioSciences (DTIL)May 17, 2025 | theglobeandmail.comvTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate UpdateMay 15, 2025 | globenewswire.comvTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 DiabetesMay 15, 2025 | globenewswire.comvTv Therapeutics (VTVT) to Release Quarterly Earnings on ThursdayvTv Therapeutics (NASDAQ:VTVT) will be releasing earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-vtv-therapeutics-inc-stock/)May 3, 2025 | marketbeat.comShort Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Expands By 42.2%vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) was the recipient of a large growth in short interest in April. As of April 15th, there was short interest totalling 22,900 shares, a growth of 42.2% from the March 31st total of 16,100 shares. Based on an average trading volume of 22,000 shares, the short-interest ratio is presently 1.0 days. Currently, 1.6% of the company's stock are sold short.May 2, 2025 | marketbeat.comvTv Therapeutics Inc. (NASDAQ:VTVT) Sees Significant Decrease in Short InterestvTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) saw a large drop in short interest in March. As of March 31st, there was short interest totalling 16,100 shares, a drop of 34.3% from the March 15th total of 24,500 shares. Based on an average daily volume of 22,400 shares, the short-interest ratio is currently 0.7 days. Approximately 1.1% of the company's stock are short sold.April 19, 2025 | marketbeat.comvTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at StockNews.comStockNews.com began coverage on shares of vTv Therapeutics in a research report on Wednesday. They issued a "sell" rating for the company.April 17, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for VTVT Q1 Earnings?vTv Therapeutics Inc. (NASDAQ:VTVT - Free Report) - HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for vTv Therapeutics in a research report issued to clients and investors on Wednesday, April 9th. HC Wainwright analyst E. Bodnar expects that the biotechnology company willApril 12, 2025 | marketbeat.comvTv Therapeutics Appoints Barry Brown as Interim CFOApril 11, 2025 | tipranks.comHC Wainwright Begins Coverage on vTv Therapeutics (NASDAQ:VTVT)HC Wainwright started coverage on vTv Therapeutics in a research note on Wednesday. They set a "buy" rating and a $36.00 price target on the stock.April 11, 2025 | marketbeat.comvTv Therapeutics initiated with a Buy at H.C. WainwrightApril 9, 2025 | markets.businessinsider.comHC Wainwright & Co. Initiates Coverage of vTv Therapeutics (VTVT) with Buy RecommendationApril 9, 2025 | msn.comvTv Therapeutics (NASDAQ:VTVT) Now Covered by StockNews.comStockNews.com initiated coverage on vTv Therapeutics in a research note on Thursday. They set a "sell" rating for the company.March 27, 2025 | marketbeat.comvTv Therapeutics (NASDAQ:VTVT) Issues Quarterly Earnings ResultsvTv Therapeutics (NASDAQ:VTVT - Get Free Report) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.55) earnings per share for the quarter, topping analysts' consensus estimates of ($0.87) by $0.32.March 21, 2025 | marketbeat.comvTv Therapeutics reports Q4 EPS (55c) vs ($1.67) last yearMarch 21, 2025 | markets.businessinsider.comvTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate UpdateMarch 20, 2025 | globenewswire.comvTv Therapeutics Inc. (NASDAQ:VTVT) Sees Significant Decline in Short InterestvTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) saw a significant decline in short interest in the month of February. As of February 28th, there was short interest totalling 24,100 shares, a decline of 13.6% from the February 13th total of 27,900 shares. Currently, 1.6% of the company's shares are short sold. Based on an average daily trading volume, of 13,300 shares, the days-to-cover ratio is currently 1.8 days.March 19, 2025 | marketbeat.comStockNews.com Begins Coverage on vTv Therapeutics (NASDAQ:VTVT)StockNews.com initiated coverage on shares of vTv Therapeutics in a report on Wednesday. They set a "sell" rating on the stock.March 19, 2025 | marketbeat.comvTv Therapeutics Inc.: vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for DiabetesMarch 18, 2025 | finanznachrichten.deAlliance Global says clinical hold lift ‘de-risking’ event for vTv TherapeuticsMarch 18, 2025 | markets.businessinsider.comvTv Therapeutics says FDA has lifted clinical hold on cadisegliatin programMarch 17, 2025 | markets.businessinsider.comvTv Therapeutics stock surges on FDA updateMarch 17, 2025 | au.investing.comVtv Therapeutics Shares Halted as FDA Clinical Hold on Diabetes Treatment LiftedMarch 17, 2025 | marketwatch.comvTv Therapeutics up after FDA lifts clinical hold on its oral diabetes treatment studyMarch 17, 2025 | msn.comvTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for DiabetesMarch 17, 2025 | globenewswire.comvTv Therapeutics (VTVT) Projected to Post Quarterly Earnings on TuesdayvTv Therapeutics (NASDAQ:VTVT) will be releasing earnings before the market opens on Tuesday, March 11, Financial Modeling Prep reports.March 5, 2025 | marketbeat.comvTv Therapeutics CFO to Resign in MarchMarch 2, 2025 | investing.comvTv Therapeutics (NASDAQ:VTVT) Earns Sell Rating from Analysts at StockNews.comStockNews.com began coverage on vTv Therapeutics in a report on Saturday. They issued a "sell" rating for the company.February 15, 2025 | marketbeat.comvTv Therapeutics (NASDAQ:VTVT) Now Covered by Analysts at StockNews.comStockNews.com assumed coverage on vTv Therapeutics in a report on Wednesday. They set a "sell" rating for the company.February 6, 2025 | marketbeat.comAlliance Global Partners Initiates Coverage of vTv Therapeutics (VTVT) with Buy RecommendationDecember 10, 2024 | msn.comCANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCERDecember 9, 2024 | prnewswire.comvTv Therapeutics to Participate in 7th Annual Evercore HealthCONx ConferenceDecember 2, 2024 | globenewswire.comvTv Therapeutics (NASDAQ:VTVT) adds US$9.5m to market cap in the past 7 days, though investors from five years ago are still down 71%November 17, 2024 | finance.yahoo.comvTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate UpdateNovember 13, 2024 | markets.businessinsider.comVTv, OnKure Terminate Cellular Drug Licensing AgreementOctober 25, 2024 | marketwatch.comvTv Therapeutics Faces License Agreement TerminationOctober 25, 2024 | markets.businessinsider.comvTv Therapeutics (NASDAQ:VTVT) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comvTv Therapeutics (NASDAQ:VTVT) Stock, Short Interest ReportOctober 4, 2024 | benzinga.comWe're Keeping An Eye On vTv Therapeutics' (NASDAQ:VTVT) Cash Burn RateAugust 16, 2024 | finance.yahoo.comVTVT Stock Earnings: vTv Therapeutics Reported Results for Q2 2024August 9, 2024 | investorplace.comvTv Therapeutics Inc.: vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate UpdateAugust 9, 2024 | finanznachrichten.devTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate UpdateAugust 8, 2024 | globenewswire.comvTv Therapeutics' stock plunges after FDA pauses High Point company's diabetes drug developmentAugust 1, 2024 | bizjournals.comWhy Is vTv Therapeutics (VTVT) Stock Down 46% Today?July 29, 2024 | investorplace.comvTv Therapeutics Inc.: vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical HoldJuly 28, 2024 | finanznachrichten.deStocks to Watch: vTv Therapeutics, BJ's Restaurants, Warner Bros. DiscoveryJuly 26, 2024 | marketwatch.comVTv Therapeutics's Cadisegliatin Program For Type 1 Diabetes Placed On Clinical Hold, Stock TanksJuly 26, 2024 | markets.businessinsider.com Get vTv Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter. Email Address VTVT Media Mentions By Week VTVT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VTVT News Sentiment▼0.720.87▲Average Medical News Sentiment VTVT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VTVT Articles This Week▼31▲VTVT Articles Average Week Get vTv Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ATXS News MDWD News SLDB News MNPR News DSGN News ENGN News TNXP News GNFT News PROK News NVCT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VTVT) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding vTv Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share vTv Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VTVT Stock Free VTVT Stock Alerts